Skip to content

Study · Case report or series · n = 1 · 2009

2 results

Exaggerated response of adrenocorticotropic hormone to growth hormone-releasing peptide-2 test in Cushing's disease. Case report.

Sakihara S, Kageyama K, Matsumoto A, Ikeda H, Tsushima Y, Naraoka M, Terui K, Nigawara T, Suda T

Neurologia medico-chirurgica1 Aug 2009Cited by 2 (Europe PMC)

PMID19707004 (opens in a new tab)DOI10.2176/nmc.49.365 (opens in a new tab)PepBankPUB-19707004
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with Cushing's disease, 100 microg GHRP‑2 raised plasma ACTH from 66 pg/ml to 2490 pg/ml.

    In plain wordsIn one woman with Cushing's disease, a GHRP‑2 dose raised blood ACTH from 66 to 2490 pg/ml.

    Peptide
    GHRP-2
    Outcome
    IncreasePlasma ACTH response to GHRP-2 test
    Study

    n = 1

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 microgAs given in this study (human).

    Measurements

    Plasma ACTH before
    66 pg/ml
    baseline
    Plasma ACTH after GHRP-2
    2490 pg/ml
    after 100 microg GHRP-2

    Source sentences

    Summary
    Plasma adrenocorticotropic hormone (ACTH) levels were greatly increased from 66 pg/ml to 2490 pg/ml (about 38-fold) in response to the administration of 100 microg human growth hormone-releasing peptide (GHRP)-2.
    2 context sentences
    Summary · context
    A 47-year-old woman presented with a pituitary microadenoma manifesting as typical Cushing's syndrome.
    Summary · context
    The diagnosis was Cushing's disease based on the endocrinological findings.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 02HumanNot a test of GHRP-2 aloneCase report or seriesMechanism

    GHRP receptor type 1a messenger ribonucleic acid was detected in the tumor of the patient.

    In plain wordsIn one woman with Cushing's disease, the receptor that GHRP‑2 acts on was found in her pituitary tumor.

    Peptide
    GHRP-2
    Outcome
    Not applicableGHRP receptor type 1a mRNA in the tumor
    Study

    n = 1

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    GHRP receptor type 1a messenger ribonucleic acid was detected in the tumor.
    2 context sentences
    Summary · context
    A 47-year-old woman presented with a pituitary microadenoma manifesting as typical Cushing's syndrome.
    Summary · context
    The diagnosis was Cushing's disease based on the endocrinological findings.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.